ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2736

Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus

Goh Murayama1, Asako Chiba 2, Tomohiro Mizuno 3, Atsushi Nomura 2, Taiga Kuga 4, HIrofumi Amano 4, Ken Yamaji 4, Naoto Tamura 4 and Sachiko Miyake 2, 1Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases, innate immunity, Systemic lupus erythematosus (SLE), T cells and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T087: Edmond L. Dubois, MD Memorial Lecture: SLE – Basic Science (2733–2737)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain: Vα7.2-Jα33 in humans and Vα19-Jα33 in mice. Previously, we reported that the activated status of MAIT cells correlated with disease activity in patients with systemic lupus erythematosus (SLE), and MAIT cells were accumulated in the kidneys from patients with lupus nephritis. Because MAIT cell deficiency reduced autoantibody production and the disease severity in FcγRIIb-/-Yaa mice, a spontaneous animal model of lupus, we investigated mechanisms by which MAIT cells enhanced autoimmune response and investigated whether MAIT cells could be therapeutically targeted in lupus.

Methods: FcγRIIb-/-Yaa mice were crossed to MR1-deficient mice lacking MAIT cells, and the levels of serum anti-dsDNA antibody and urinary albumin were measured. The severity of nephritis was assessed histologically. T and B cell subsets in the spleen and kidneys at 2 months of age were analyzed by using flow cytometry. To evaluate whether inhibition of MAIT cell activation suppress the disease course of lupus, FcγRIIb-/- Yaa mice were treated with isobutyryl 6-formyl pterin (i6-FP), a suppressive MR1 ligand, orally three times weekly for 4 weeks starting at 4 weeks of age. B cells from FcγRIIb-/-Yaa mice were stimulated with lipopolysaccharide in the presence of MAIT cells and autoantibody production was assessed by ELISA.

Results: Activated MAIT cells were infiltrated into the kidneys of FcγRIIb-/-Yaa mice. Reduced autoantibody production and disease severity by MR1 deficiency was associated with reduced germinal center and T cell responses in FcγRIIb-/-Yaa mice. The suppression of MAIT cell activation by i6-FP administration decreased serum anti-dsDNA antibody levels and the deposition of IgG and C3 in the glomeruli. i6-FP administration also reduced germinal center responses and activated T cell infiltration into kidneys in FcγRIIb-/-Yaa mice. MAIT cells directly enhanced autoantibody production by B cells in vitro, and this was markedly reduced by blocking CD40L-CD40 or the MR1-TCR pathway.

Conclusion: MAIT cells exacerbated the disease severity of lupus by enhancing autoantibody production and tissue inflammation in FcγRIIb-/- Yaa mice. MAIT cells enhanced autoantibody production by B cells dependent on the CD40-CD40L and TCR pathways. Together with our previous findings in patients with SLE, MAIT cells may contribute to lupus pathology and serve as potential novel therapeutic target for autoimmune diseases such as SLE.


Disclosure: G. Murayama, None; A. Chiba, None; T. Mizuno, None; A. Nomura, None; T. Kuga, None; H. Amano, None; K. Yamaji, ASAHI KASEI PHARMA, 2, Astellas pharma, 2, 8, bristol myers, 8, Chugai Pharma, 2, Janssen Pharma, 8, Mitsubishi-Tanabe Pharma, 2, 8, Sanofi Pharma, 8, Takeda Pharma, 2; N. Tamura, AbbVie GK, 8, AbbVie pharma, 8, ASAHI KASEI MEDICAL, 2, ASAHI KASEI PHARMA, 2, astellas pharma, 2, 8, Astellas Pharma Inc., 2, 8, AYUMI PHARMA, 2, AYUMI Pharmaceutical Corporation, 2, bristol myers, 8, Bristol-Myers Squibb, 8, Chugai Phamaceutical Co. Ltd., 2, Chugai Pharma, 2, Eisai Co., Ltd., 2, Eisai Pharama, 2, Janssen Pharma, 8, Janssen Pharmaceutical K.K., 8, Mitsubishi Tanabe Pharma Corporation, 2, 8, Mitsubishi-Tanabe Pharma, 2, 8, Sanofi K.K., 8, Sanofi Pharma, 8, Takeda Pharma, 2, Takeda Pharmaceutical Company Ltd., 2; S. Miyake, Bristol myers squibb, 2, Bristol-Myers Squibb, 2, Pfizer, 2, Pfizer Japan Inc., 2, Taiho pharmaceutical, 8, TAIHO PHARMACEUTICAL CO., LTD., 8.

To cite this abstract in AMA style:

Murayama G, Chiba A, Mizuno T, Nomura A, Kuga T, Amano H, Yamaji K, Tamura N, Miyake S. Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/mucosal-associated-invariant-t-cells-can-be-therapeutically-targeted-in-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mucosal-associated-invariant-t-cells-can-be-therapeutically-targeted-in-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology